| Title: |
Primary CNS Lymphoma in India: A 17-Year Experience From the All India Institute of Medical Sciences |
| Authors: |
Mukesh Patekar, Narayan Adhikari, Ahitagni Biswas, Vinod Raina, Lalit Kumar, Bidhu Kalyan Mohanti, Ajay Gogia, Atul Sharma, Atul Batra, Sameer Bakhshi, Ajay Garg, Sanjay Thulkar, Meher Chand Sharma, Sreenivas Vishnubhatla, Saphalta Baghmar, Ranjit Kumar Sahoo |
| Source: |
Journal of Global Oncology, Vol 5, Pp 1-9 (2019) |
| Publisher Information: |
American Society of Clinical Oncology, 2019. |
| Publication Year: |
2019 |
| Collection: |
LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens |
| Subject Terms: |
Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282 |
| More Details: |
PURPOSE: The information about the outcome of primary CNS lymphoma (PCNSL) in India is scarce, because there is no population-based or large hospital-based data. MATERIALS AND METHODS: This is a retrospective study that spanned 17 years (2001 to 2017) to study the outcome of PCNSL at the All India Institute of Medical Sciences (AIIMS), which is a tertiary care center in Northern India. RESULTS: Only one of 99 patients was positive for HIV serology. Diffuse large B-cell lymphoma was the most common histology (97.7%). The median patient age was 50 years (range, 13 to 70 years), and the ratio of men to women was 1.9. The median duration of symptoms before diagnosis was 3.5 months (range, 0.5 to 48 months), and 58.5% had a performance status (PS) of 3 or more. Multiple intracranial lesions were present in 81.8% of patients. Surgical resection was performed in 45%, and approximately 22% of patients were ineligible for treatment. Most patients (n = 73) were treated with high-dose methotrexate (HDMTX)–based regimens (ie, methotrexate, vincristine, and procarbazine with or without rituximab). Pharmacokinetic monitoring of methotrexate was not available at our center. HDMTX-related mortality was 3.9%. The median follow-up duration, event-free survival (EFS), and overall survival (OS) were 34 months, 20.4 months, and 31.7 months, respectively. Addition of rituximab (n = 27) to MVP resulted in a higher objective response rate (88.9% v 73.9% without rituximab; P = .12), complete remission (81.5% v 56.5%; P = .03), 2-year EFS (57.3% v 40.4%; P = .02), and 2-year OS (61.6% v 53.4%; P = .056). CONCLUSION: This is the largest study of PCNSL from India. The patients were immunocompetent and young but presented with a high-burden disease that precluded treatment in approximately 22%. The treatment with HDMTX appears safe without pharmacokinetic monitoring. The outcome is comparable to those observed in the West, and rituximab use showed additional benefit. There are notable barriers with respect to management of PCNSL in the real world, and efforts are required to improve the outcome more. |
| Document Type: |
article |
| File Description: |
electronic resource |
| Language: |
English |
| ISSN: |
2378-9506 |
| Relation: |
https://doaj.org/toc/2378-9506 |
| DOI: |
10.1200/JGO.18.00124 |
| Access URL: |
https://doaj.org/article/b48fe5c17c034e3497a5ffdcad239572 |
| Accession Number: |
edsdoj.b48fe5c17c034e3497a5ffdcad239572 |
| Database: |
Directory of Open Access Journals |
